What was known before
Patients with heart failure often also have kidney disease. Many large trials of pharmacotherapies for heart failure, including those for ACE-I and ARB, did not include patients with significant kidney dysfunction and so use of these medications in this population has remained controversial.
Introduction
Heart failure (HF) is one of the most common cardiovascular syndromes, with a prevalence of approximately 2% in North American adults older than 45 years of age, and a lifetime risk of over 20%. 1 HF is characterized by periodic exacerbations with nearly 1 million hospitalizations for HF in the United States each year. 1 HF is associated with significant mortality, with survival estimates of 50% and 10% at 5 and 10 years, respectively. The use of evidence-based pharmacotherapy is crucial to improve the outcomes and costs of caring for HF. 2 There is strong evidence that Angiotensin converting enzyme inhibitors (ACE-Is) 3, 4 or angiotensin receptor blockers (ARBs) 5 improve survival in patients with HF with reduced left-ventricular ejection fraction (LVEF).
Reduced kidney function is prevalent in over half of patients with HF and is an independent risk factor for hospitalization, and mortality. 6, 7 However, the optimal management of patients with coexisting kidney disease is controversial because most trials of ACE-I and ARBs excluded patients with moderate to severely reduced kidney function. Furthermore, worsening renal function accompanying HF exacerbations may lead physicians to avoid these medications. There is little information on contemporary patterns of ACE-I/ARB use and outcomes in patients with HF according to kidney function. 2 We examined pharmacy-prescribing data to characterize patterns of ACE-I/ARB use according to kidney function in a cohort of patients recently hospitalized for HF. We also examined the relationship between ACE-I/ARB use and survival following a HF hospitalization and explored whether this association differed by the level of discharge kidney function.
Methods

Study Population
We formed our study cohort from the Cardiac Admissions Module of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) database. The Admissions Module of APPROACH prospectively collects demographics, clinical data, comorbidities, treatment information including admission and discharge medications, and vital statistics from patients hospitalized under the care of cardiology services in 3 centers in Southern Alberta, Canada. 8 Our cohort included adults admitted between January 1, 2008, and September 31, 2012, with a clinical diagnosis of HF at time of discharge identified by the attending physician. To be included in the cohort, patients required a serum creatinine before or during their admission. Patients who died during their index hospitalization or were discharged to an extended care facility were excluded.
Measurements of Kidney Function
We obtained serum creatinine measurements from the Alberta Health Services provincial laboratory data repository. The last creatinine prior to discharge was used to estimate Glomerular Filtration Rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI). 
Measurement of Medication Prescriptions
We obtained outpatient prescription drug data prior to and following the index hospitalization using the Pharmaceutical Information Network (PIN) for the province of Alberta. Alberta's community pharmacies are mandated to contribute their drug dispensing data to the PIN, and approximately 96% of the drug dispensations from community pharmacies are available in this system. Medications used during hospital admission were obtained from the APPROACH Admissions Module. We categorized individual drug records into classes: ACE-I/ARBs, beta-blockers, loop-diuretics, and mineralocorticoid receptor antagonists (MRA). We characterized medication use within fixed time periods relative to the index HF hospitalization, including within the year prior to admission, during hospitalization, 1 month, 3 months, and 1-year post discharge based on one or more records of dispensing within these time periods.
Statistical Analyses
Continuous variables were summarized as median and interquartile range. Binary variables were summarized as absolute number and proportion. We compared participant characteristics based on discharge eGFR using analysis of variance (ANOVA) for continuous variables and a chisquared test for categorical variables. We also used chisquared tests to examine differences in the proportion of patients using ACE-I/ARB or other cardiovascular medications according to eGFR category within each of the specified time periods.
Patients were followed from their date of hospital discharge until the study end date (April 30, 2014) or death. We examined the associations between ACE-I/ARB use and mortality after hospital discharge using Cox-proportional hazards models, with adjustment for age, sex, eGFR, BMI, smoking status and comorbidities including diabetes mellitus, hypertension, hyperlipidemia, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass grafting, peripheral vascular disease, cerebrovascular disease, liver disease, gastrointestinal disease, malignancy, psychiatric disorder, alcohol abuse, beta-blocker, loopdiuretic, and spironolactone use. These models incorporated ACE-I/ARB exposure as a time-varying exposure, in which time at risk prior to the first identified ACE/ARB prescription was attributed to untreated status and time following ACE-I/ ARB prescription was attributed to treated status. We tested interactions between ACE-I/ARB use and eGFR category and used the model including the interaction terms to obtain stratum specific estimates by eGFR category. The proportional hazards assumption was tested using Schoenfeld residuals and was satisfied for all models. We performed all analyses using SAS (version 9.3; SAS Institute Inc., Cary, NC). The Conjoint Health Ethics Research Board at the University of Calgary approved this study.
Results
Cohort Formation and Patient Population
We identified 1611 hospitalized patients from the APPROACH database with a discharge diagnosis of HF and a serum creatinine measurement within the cohort entry period. After excluding 91 patients who died during their index hospitalization and 104 patients who were discharged to an extended care facility, there were 1404 patients remaining in the final cohort ( Figure 1 ).
The median (interquartile range) duration between discharge date and the day of the last serum creatinine measurement used to define discharge eGFR was 0 (2.0) days. Table 1 shows the baseline characteristics of the cohort by discharge eGFR. Patients were predominately male in all eGFR categories, with male prevalence ranging from 57% to 68%. Cardiac risk factors (including older age, hypertension, diabetes and dyslipidemia) as well as established vascular disease (cerebrovascular disease and prior myocardial infarction) were more prevalent with lower eGFR.
Patterns of ACE-I/ARB Use According to Kidney Function
Patients in all eGFR categories showed increasing ACE-I/ ARB use over time following hospital discharge; however, the proportion of patients using an ACE-I/ARB by significantly differed by eGFR at 30 days (P = .002), 3 months (P < .001), and 1 year (P < .001), and compared to those with eGFR > 90 mL/min/1.73 m , the proportion using an ACE-I/ARB declined significantly from 74.0% in the year before admission, to 61.8% at 1 year after discharge (P < .0001).
Comparisons With Other Cardiovascular Medication Use
Contrary to the pattern seen with ACE-I/ARB, beta-blocker use following hospital discharge did not significantly differ by eGFR level at 30 days, 3 months, or 1 year following hospital discharge. However, loop-diuretic use significantly differed at 3 months (P = .009) and 1 year (P = .002), and was higher among patients with eGFR 30-44 and < 30 than those with eGFR > 90 mL/min/1.73 m 2 ( Supplementary Figures  1-3) . Similar to the pattern seen with ACE-I/ARB, use of MRA significantly differed at 30 days (P < .0001), 3 months (P = .002), and 1 year (P < .0001), and was lowest among patients with eGFR <30 mL/min/1.73 m 
Figure 2.
Percentage of patients in the Southern Alberta cohort hospitalized with heart failure receiving an ACE-I/ARB at varying times before and after hospital admission, according to discharge eGFR.
Note. ACE-I = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; eGFR = estimated glomerular filtration rate.
Figure 3.
Adjusted hazard ratios with 95% confidence intervals for the association between ACE-I/ARB use and all-cause mortality in Southern Alberta cohort hospitalized with heart failure, stratified by discharge eGFR, and for the overall cohort.
Note. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate.
In unadjusted Cox-proportional hazards models accounting for time-varying medication exposure, lower levels of discharge eGFR were associated with incrementally higher mortality ( There was no significant difference in the association between ACE-I/ARB use and mortality at different levels of discharge eGFR (p-interaction 0.753). The overall and eGFR stratum specific estimates are shown in Figure 3 .
Discussion
In this cohort study, we found that patients with HF and all levels of kidney function had an increase in use of ACE-I/ARB in the year after hospital discharge, with the proportion exceeding 70% at 1 year. However, we also observed that reduced kidney function was associated with significantly lower use of ACE-I and ARB, which persisted over that time frame. This pattern significantly differed from that of beta-blocker use. Furthermore, we observed a 25% lower adjusted relative risk of 1-year mortality associated with ACE-I or ARB use among patients with HF, with no difference in the association at different levels of discharge eGFR. Our finding that ACE-I/ARB use is associated with improved survival in HF is similar to findings from other observational studies and clinical trials. The landmark studies of Left Ventricular Dysfunction 10 (SOLVD) and the Survival And Ventricular Enlargement 11 (SAVE) demonstrated 4.5% and 14% absolute reductions in all-cause death with ACE-I/ ARB use in systolic HF. Subsequent subgroup analysis of the SOLVD trial found that enalapril remained associated with reduced all-cause mortality among patients with moderate and severe renal dysfunction without adverse kidney effects, and no statistical interaction between eGFR level and enalapril treatment was found in the trial. 12 Similarly in the CHARMAlternative trial, ARB treatment lead to a 23% relative risk reduction for cardiovascular death or hospital admission for HF in patients with systolic dysfunction intolerant of ACE-I. 13 Our findings are similar to the results of other cohort studies showing improved outcomes with the use of ACE-I/ARB in patients with HF and moderate to severe CKD. [14] [15] [16] [17] [18] A retrospective analysis of the Minnesota Heart Survey reported lower mortality for patients treated with ACE-I or ARBs across all stages of CKD, excluding patients receiving dialysis. 19 Moreover a large retrospective cohort study evaluating elderly patients with LVEF <40% found that prescription of ACE-I upon hospital discharge was associated with the largest reduction in mortality among patients with the most severe renal dysfunction (creatinine > 265 μmol/L).
14 Similar findings have also been observed in the subspecialty HF care setting in Canada, including an Alberta heart function clinic. 20 Most recently, data from the Swedish Heart Failure Registry also reported increased mortality in patients with lower eGFR, but lower relative risks of death in those who received target doses of guideline-directed HF medical therapy including ACE-I, ARB, beta-blockers (BB), and mineralocorticoids receptor antagonists (MRA). [21] [22] [23] Patients with kidney disease have been frequently excluded from large multicenter cardiovascular therapeutics trials, with one review noting their exclusion from 56% of major clinical trials. Moreover, only 5% of original trial publications reported the proportion of patients with CKD and 10% reported baseline renal function, further raising uncertainty about the generalizability of findings to patients with CKD. 24 Our findings add to the current literature, by quantifying the current disparity in use of ACE-I/ARB in HF patients with reduced kidney function and by demonstrating similar associations with improved survival in these patients.
The driver for disparity in use of ACE-I/ARB that we observed in patients with HF and kidney disease is uncertain. The difference may be attributable to clinicians' concerns regarding the applicability of current evidence to the CKD and HF population since previous large trials excluded patients with severe renal dysfunction and existing recommendations have been based on secondary analyses of these trials. 20 Furthermore, ACE-I/ARB avoidance may result from apparent safety concerns such as hyperkalemia, hypotension, or a rise in serum creatinine, which frequently accompany decompensated HF. 25, 26 However, small rises in serum creatinine in response to ACE-I/ ARB have been associated with long-term preservation of kidney function in CKD, and a lack of prognostic significance in HF as they may occur due to functional effects on eGFR without evidence of structural kidney injury. [27] [28] [29] Hyperkalemia is a justifiable safety concern with ACE-I/ARB use, as ACE-I/ARB are the most common medication associated with hyperkalemia, leading to discontinuation or dose reduction in 29% of patients. 30 However, elevations of serum potassium were usually modest (<1 mEq/L) with life threatening hyperkalemia occurring rarely. Higher baseline serum potassium, renal dysfunction, and use of multiple RAAS antagonists have been associated with a higher risk of hyperkalemia, suggesting that strategies to predict the risks of clinically significant hyperkalemia are possible. 20, 31 Furthermore, randomized controlled trials of ACE-I/ARB in patients with early stage and advanced proteinuric CKD have demonstrated that these agents can be used effectively and safety in most patients across the stages of CKD. 32, 33 Strengths of our study include the detailed characterization of a large cohort of HF patients combined with prospectively ascertained clinical, laboratory, and medication information. Additionally, we captured dispensed prescriptions as opposed to medications reported by patients or on discharge summaries which may not reflect community prescriptions. However, there are several important limitations to our study. First, due to its observational design, our study is susceptive to treatment-selection bias, whereby patients at highest risk for poor outcomes may not receive ACE-I/ARB. However, the relationship between treatment and outcomes that we observed is in keeping with benefits reported from randomized trials. Second, we characterized patients based on discharge eGFR, which did not allow us to identify contributions due to chronic kidney disease versus acute kidney injury. However, fluctuations in kidney function are common in the setting of HF, and use of the most recent measure of kidney function is relevant to clinical decision making about outpatient medication prescribing upon hospital discharge. Third, we did not have reliable data on LV function and this was excluded from our analysis. Inclusion in our cohort did not depend of LVEF measurement, and therefore our study includes patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction (HFpEF). Although there is stronger evidence for the use of ACE-I and ARB in HFrEF than HFpEF, benefits of ACE-I/ARB therapy in HFpEF include lower risk of hospitalization observed in the Candesartan in Heart Failure Reduction in Mortality CHARM-Preserved trial 34 and the Perindopril in Elderly People with Chronic Heart Failure Study. 35 Fourth, we did not have information surrounding the cause of HF exacerbation.
Importantly, we lacked information on adverse medication safety events such as hyperkalemia, acute kidney injury, and hypotension, which may have contributed to lower use of ACE-I/ ARB in participants with reduced kidney function. Observational studies have demonstrated an increasing incidence of hyperkalemia with ACE-I/ARB in CKD; however, there has been wide variation in estimates of frequency, with incidence as low as 2.8% in some studies 36 and as high as 51% in other studies of patients with stage G5 CKD. 37 In the largest recent observational study the risk of hyperkalemia (serum potassium ⩾ 5.5mM) was 7.7% in patients with CKD treated with an ACE-I or ARB. 38 Recommendations in guidelines for HF highlight that hyperkalemia may prompt a switch from ACE-I/ARB therapy to other vasodilators when persistent hyperkalemia despite dietary intervention, dosage reduction, and removal of other agents known to increase serum potassium. 39 Worsening kidney function may also prompt a switch from ACE-I/ARB therapy to other agents when reduced kidney function persists despite modification of dose, rechallenge, and removal of other potential nephrotoxic agents, or when there is a concern it may precipitate need for renal replacement therapy. These issues likely contribute to the lower us of ACE-I and ARB in patients with moderate to severely reduced kidney function in our study.
In conclusion, we identified lower use ACE-I and ARB after hospitalization with HF in patients with moderate to severely reduced kidney function. Nonetheless, we observed lower mortality among patients who received ACE-I and ARBs with no evidence of a significant modification of this associations across different eGFR strata. Further research is needed to develop and test strategies to support the safe use of ACE-I and ARB in patients with HF and kidney disease.
Clinical Perspectives
Patients with HF often develop coexisting kidney disease. Many large trials of pharmacotherapies for HF, including those for ACE-I and ARB, did not include patients with significant renal dysfunction and so use of these medications in this population has remained controversial. In this observational study, the use of ACE-I or ARB was significantly lower in patients with reduced kidney function after a recent hospitalization for HF. However, ACE-I or ARB use was associated with a 25% lower adjusted relative risk of 1-year mortality, and this association was consistently observed across all levels of kidney function.
Translational Outlook
Current prescribing patterns and outcomes associated with ACE-I/ARB use point to the need for further research on strategies for safe use of ACE-I and ARB in patients with HF and advanced coexisting kidney disease.
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